Momenta Phama (MNTA) Prices 14.516M Share Common Offering at $15.50/Sh

Momenta Phama (MNTA) Announces Dr. Jane F. Barlow to Board

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors.

Dr. Barlows expertise in market access and commercial pricing will be invaluable as we continue to develop our pipeline of novel autoimmune therapeutics, said Craig Wheeler,... More

Pre-Open Movers 12/11: (PTI) (OLLI) (PLAB) Higher (ITRM) (GME) (PLCE) Lower (more...)

Today's Pre-Open Movers

Iterum Therapeutics plc (Nasdaq: ITRM) 46.2% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.

GameStop (NYSE: GME)... More

After-Hours Movers 12/10: (ASPU) (OLLI) (PLAY) Higher; (ITRM) (GME) (AQST) Lower (more...)

Today's After-Hours Movers

Iterum Therapeutics plc (Nasdaq: ITRM) 38.6% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.

GameStop (NYSE:... More

Momenta Phama (MNTA) Announces Proposed $200M Share Common Offering

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock. Momenta also expects to grant the underwriters of the offering an option to purchase up to an additional $30,000,000 of shares of... More